Premium
New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors
Author(s) -
Becker Jürgen C.,
Ugurel Selma,
Bröcker EvaBettina,
Schrama David,
Houben Roland
Publication year - 2006
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2006.05920.x
Subject(s) - epigenetics , histone deacetylase , histone , cancer research , methyltransferase , cancer epigenetics , biology , dna methylation , proteasome , histone methyltransferase , bioinformatics , methylation , genetics , gene , gene expression
Summary Recent results from basic and translational research on tumor genesis and progression establish the basis for future therapeutic approaches. Targeted therapeutics are tailored toward the molecular abnormalities that cause tumor progression and could potentially provide an effective, non‐toxic therapeutic approach in a broad range of cancers including melanoma. Cancer is as much a (cyto)genetic disease as it is an epigenetic disease. Indeed, the fate of the cell depends on a delicate balance between expression and repression of genes. The notion that drastic changes in DNA methylation and histone modifications are present in a variety of human tumors has prompted the development and characterization of epigenetic drugs. Inhibitors of histone deacetylases and methyltransferases as well as of the proteasome are covered in this review.